• Skip to primary navigation
  • Skip to main content
  • Skip to footer
NICO CorporationSecondary logo

NICO Corporation

Dedicated to revolutionizing minimally invasive neurosurgery

  • Home
  • Patients
  • Professionals
    • Our Capabilities
    • Our Integrated System
    • Our Surgical Focus
    • Our Impact
    • Published Data
    • Investigator Initiated Study Program
      • IIS Program Overview
      • IIS Areas of Interest (AOIs)
    • Donation Request
    • Global Distribution
    • NICO Technologies for Animal Health
    • Neurosurgeon Education
  • Company
    • Our Mission
    • Our Leadership Team
    • News & Events
    • Careers
  • LinkedIn
  • Twitter
  • YouTube

Brain Metastases

Home » Our Surgical Focus » Brain Metastases

What is the incidence of brain METs in the United States?

Of All Cancer Patients

20 – 40%

Will Develop a Brain MET1
NICO-people-icon-20-to-40-percent

 

Annual MET Incidence2

20% Will Become Symptomatic

200,000 Cases AnnuallyBrain-METS-20-percent-symptomatic-NICO 

Brain METs are the most common intracranial neoplasm in adults3

 

 


What challenges have been encountered with conventional surgical approaches?

  1. Morbidity – Complications – Edema3-8
  2. Increased risk of leptomeningeal spread due to ultrasonic aspirators.9,10
  3. Hemostasis management in MIS approaches.11
  4. Harvesting tissue in MIS approaches.

 


 

How does the MIPS approach with NICO’s integrated systems solution overcome these challenges?

Challenge #1 – Morbidity – Complications – Edema
Solution: Minimally disruptive, navigable access to eloquent areas.
BrainPath is designed for trans-sulcal access
BrainPath is designed for navigable, trans-sulcal access with an a-traumatic conical tip that gradually dilates the tissue during cannulation
BrainPath sheath
BrainPath sheath acts as a protective portal for displaced neural tissue
Challenge #2 – Increased risk of leptomeningeal spread due to ultrasonic aspirators.
Solution: Using the NICO Myriad NOVUS the surgeon can choose to employ a pseudo en bloc technique to keep the external capsule intact while debulking the inner section of the MET.

Challenge #3 – Hemostasis management in MIS approaches.
Solution: Room for bimanual microsurgical technique.

13.5mm and 11mm BrainPath diameters
Both the 13.5mm and 11mm BrainPath diameters can accommodate two hands in the surgical field to enable basic hemostasis principles of microsurgery to be applied


Challenge #4 – Harvesting tissue in MIS approaches.
Solution: High yield tissue collection with NICO Myriad NOVUS and Automated Preservation System.

  • Myriad NOVUS resects tissue in a mechanical, non-ablative and non-thermal format so the cellular viability of the specimen is still maintained with minimal crushed effect.
  • The tissue filter of the Automated Preservation System ensures all tissue is resected through the device in a sterile, closed tissue trap that mitigates tissue degradation by limiting the sample’s exposure to the atmosphere.

NICO Automated Preservation System
NICO Myriad Tissue Filter
NICO Myriad Tissue Filter
NICO Myriad Tissue Filter

 

Key Publications

Zada et al. Multicenter Investigation of Channel-Based Subcortical Trans-sulcal exoscopic resection of metastatic brain tumors: A retrospective case series. Operative Neurosurgery. June 2018. doi:10.1093/ons/opy079


Day J.D., Transsulcal Parafascicular Surgery Using BrainPath for Subcortical Lesions. Clinical Neurosurgery. 2017; 64(1):151–156. doi:10.1093/neuros/nyx324


Mampre et al. Minimally invasive resection of intra-axial posterior fossa tumors using tubular retractors. World Neurosurgery (2018), doi:10.1016/j.wneu.2018.08.049


Chaichana K et al. Resection of Deep-Seated Metastatic Brain Tumors. Journal of Neurological Surgery Part – A IN PRESS. 2018.

 

 


 

Citations

  1. Bhangoo SS et al. Evidence-Based Guidelines for the Management of Brain Metastases. Neurosurg Clin N Am 2011; 22:97-104 doi:10.1016/j.nec.2010.09.001
  2. Rahmathulla G et al. The molecular biology of brain metastasis. J Oncol 2012: 723541 http://dx.doi.org/10.1155/2012/723541
  3. Patel AJ et al. Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. Journal of Neurosurgery, May 2015. 122:1132-1143. doi:10.3171/2014.9.JNS13939
  4. Stark AM et al. Surgical treatment for brain metastases: prognostic factors and survival in 177 patients. Neurosurg Rev. 2005, 28: 115-119. doi:10.1007/s10143-004-0364-3
  5. Baker CM et al. Simultaneous resection of multiple metastatic brain tumors with multiple keyhole craniotomies. World Neurosrugery. October 2017. 106: 359-367. doi:10.1016/j.wneu.2017.06.118
  6. Dubey A et al. Complications of posterior cranial fossa surgery–an institutional experience of 500 patients. Surg Neurol. 2009;72:369-375. doi:10.1016/j.surneu.2009.04.001
  7. Hadanny A et al. Craniectomy Versus Craniotomy for Posterior Fossa Metastases: Complication Profile. World Neurosurg. 2016;89:193-198. doi:10.1016/j.wneu.2016.01.076
  8. Brell M et al. Factors influencing surgical complications of intraaxial brain tumours. Acta Neurochir (Wien). 2000;142:739-750
  9. Suki D, et al. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. Journal of Neurosurgery, February 2008 / Vol. 108 / No. 2 doi:10.3171/JNS/2008/108/2/0248
  10. Ahn JH, et al. Risk for leptomeningeal seeding after resection for brain metastases: Implication of tumor location with mode of resection. Journal of Neurosurgery, May 2012 / Vol. 116 / No. 5 doi:10.3171/2012.1.JNS111560
  11. Jackson C. et al. Minimally Invasive Biopsies of Deep Seated Brain Lesions Using tubular retractors under exoscopic visualization. Journal of Neurological Surgery. doi:10.1055/s-0037-1602698

Footer

OUR MISSION is SIMPLE

We provide proven and patented technologies that integrate imaging and intervention for a safe, minimally disruptive approach to brain surgery. This integration drives efficiencies for the patient, surgeon and healthcare provider.

Customer Service

 Tel: (317) 660-7118
 Email Us

Follow NICO Here

  • LinkedIn
  • Twitter
  • YouTube
Social Media Links

Search Our Website

privacy policy   ·    terms of use   ·    patents    ·   labeling

Copyright © 2023 · Nico Corporation · NICO Myriad and BrainPath are “tools” not “treatments”. Physicians should use their best judgment and clinical experience when deciding how to use the Myriad and BrainPath. The latest information, including contraindications, warnings and precautions can be obtained by consulting product labeling or your local NICO representative.